A drug tested on patients treated for colon cancer at Memorial Sloan Kettering, one of the cancer treatment centers in the United States, has achieved 100% success. Experts rated the treatment method used for the first time in the world as promising. Patients who participated in treatment and recovered spoke for the first time.
As cancer studies have recently gained momentum all over the world, the promising research results have generated excitement in the scientific world. The most striking of these developments took place in New York, USA. A new cancer drug tested on 18 colon cancer patients at Memorial Sloan Kettering Cancer Center in Manhattan has been 100% successful.
It was announced that the drug used against colon cancer, one of the deadliest cancers in the world, was successful in all 18 participants and all of them beat the cancer.
Speaking to The New York Times, medical oncologist Luis Alberto Diaz Jr., one of the chief experiments at MSK Cancer Center, said: “I think this is the first time in cancer-related research. “
THEY USE MEDICATION EVERY THREE WEEKS FOR SIX MONTHS
During the treatment process, patients were given a drug called dostarlimab every three weeks for six months.
The drug, dostarlimab, was given to each patient every three weeks for six months.
Study participants were offered chemotherapy or surgery that could lead to bowel or urinary dysfunction. However, all patients started trying drugs instead of alternative methods.
“No trace of tumor was found”
At the end of the process, there was no trace of tumor in the samples taken from the patients, and they survived the whole painful process of cancer treatment.
Oncologist at Memorial Sloan Kettering Cancer Center, Dr. “There were so many tears of happiness,” Andrea Cercek told The New York Times.
Sascha Roth, one of the patients who participated and recovered from the study, said: “I was told that I would need chemotherapy before taking part in the study. Or it was said that you would undergo radiotherapy and surgery. Compared to that, immunotherapy was like a walk in the park,” he said.
Cercek said it’s “too early to tell if all patients will stay in the recovery process, if the drug will work in different types of rectal cancer, but the results are cause for great optimism.”
Avery Holmes, one of the names who took part in the treatment and recovered, said: “First you think you’re dead. Or at least he would completely lose his rectum and couldn’t heal … And then wow! It’s an incredible feeling,” he said.
WHAT HAPPENED 6 TO 25 MONTHS LATER?
Experts also announced that they had not encountered cancer recurrence after six to 25 months in the 18 patients who took part in the study.
Researchers believed that ‘dostarlimab’ might help shrink or eliminate tumors in patients, based on previous experiences with a drug in the same class called ‘pembrolizumab’. Pembrolizumab and dostarlimab are known as “checkpoint inhibitor” drugs that increase the ability of immune cells to identify and attack cancer cells.
Experts, through this treatment method, colon cancer patients, instead of a painful and painful recovery process, hoped to have a simple process that does not affect their lives.
Oncologist at the University of North Carolina Lineberger Comprehensive Cancer Center, Dr. “If immunotherapy can be a cure for rectal cancer, eligible patients may no longer have to settle for functional trade-offs for treatment,” Hanna Sanoff said in a statement about the research.